SCHEMBL235451

SCHEMBL235451

Cc1cc2ncc3cc(-c4ccccc4)c(-c4ccc(N)cc4)nc3n2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.46
RAB9A P51151 7/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
HPGD P15428 3/20 0.46
TP53 P04637 2/20 0.46
AKT1 P31749 5/20 0.43
AKT2 P31751 5/20 0.43
KDM4E B2RXH2 3/20 0.41
PKM P14618 1/20 0.41
AURKA O14965 1/20 0.41
ALDH1A1 P00352 3/20 0.40
STAT1 P42224 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
GFER P55789 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL234236 0.88 NPC1 (0.41) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL18797689 0.87 NPC1 (0.41) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL239466 0.87 NPC1 (0.41) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL238251 0.87 AKT1 (0.47) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL235955 0.86 AURKA (0.41) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL16986811 0.84 AKT1 (0.40) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL237338 0.84 KDR (0.48) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL235739 0.84 AKT1 (0.66) AKT1AKT2
SCHEMBL238695 0.83 AKT1 (0.37) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL236154 0.82 ALDH1A1 (0.44) KMT2AHPGDAKT1AKT2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP claimed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US claimed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US claimed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 NPC1 1127/4885RAB9A 778/4885SMN1; SMN2 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.